
    
      This is a multi center, open label, long term safety study in pediatric subjects 6 through 17
      years of age, inclusive, with a diagnosis of ADHD associated insomnia. Subjects who complete
      Study 190 246 (Rollover subjects) and meet the study enrollment criteria will be allowed to
      participate in this long term safety study. Additionally, Treatment na√Øve subjects will be
      enrolled in this long term safety study in order to meet the overall subject enrollment
      objective of obtaining 100 subjects with 12 months of treatment. This study was previously
      posted by Sepracor Inc. In October 2009, Sepracor Inc. was acquired by Dainippon Sumitomo
      Pharma., and in October 2010, Sepracor Inc's name was changed to Sunovion Pharmaceuticals
      Inc.
    
  